alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM JASON
INCORPORATED CONSOLIDATED BALANCE SHEET AT JUNE 26, 1998, AND CONSOLIDATED
INCOME STATEMENT FOR THE SIX MONTH PERIOD ENDED JUNE 26, 1998.  AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-25-1998
<PERIOD-START>                             DEC-27-1997
<PERIOD-END>                               JUN-26-1998
<CASH>                                           30375
<SECURITIES>                                         0
<RECEIVABLES>                                    54512
<ALLOWANCES>                                         0<F1>
<INVENTORY>                                      43427
<CURRENT-ASSETS>                                145060
<PP&E>                                          162516
<DEPRECIATION>                                   74848
<TOTAL-ASSETS>                                  305426
<CURRENT-LIABILITIES>                           104653
<BONDS>                                          68263<F2>
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         35253
<OTHER-SE>                                       80170
<TOTAL-LIABILITY-AND-EQUITY>                    305426
<SALES>                                         190067
<TOTAL-REVENUES>                                190067
<CGS>                                           147633
<TOTAL-COSTS>                                   147633
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                3555
<INCOME-PRETAX>                                  10927
<INCOME-TAX>                                      4263
<INCOME-CONTINUING>                               6664
<DISCONTINUED>                                    1278
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      7942
<EPS-PRIMARY>                                     0.39<F3>
<EPS-DILUTED>                                     0.37
<FN>
<F1>COMPANY PRESENTS RECEIVABLES ON A NET BASIS IN COMPLIANCE WITH ARTICLE 10
REGULATION S-X.
<F2>INCLUDES ALL NON-CURRENT PORTION OF DEBT OBLIGATIONS.
<F3>THE EPS UNDER THE EPS PRIMARY TAG REPRESENTS BASIC EARNINGS PER SHARE IN
ACCORDANCE WITH STATEMENT OF FINANCIAL ACCOUNTING STANDARD NO. 128 EARNINGS PER
SHARE.
</FN>
        

</TABLE>
<PAGE>   1

                                                                   EXHIBIT 23.03


               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We consent to the reference to our firm under the caption "Experts" in the
Registration Statement (Form S-4) and related Proxy Statement/Prospectus of
Corixa Corporation for the registration of 4,716,860 shares of its common stock
and to the incorporation by reference therein of: (i) our report dated February
22, 1999 with respect to the financial statements of Anergen, Inc. included in
Current Report on Form 8-K of Corixa Corporation dated August 9, 1999; and (ii)
our report dated February 6, 1998 except for the second paragraph of Note 1, as
to which the date is December 21, 1998 with respect to the financial statements
of Anergen, Inc., included in Current Report on Form 8-K of Corixa Corporation
dated February 12, 1999, filed with the Securities and Exchange Commission.


Seattle, Washington                                          ERNST & YOUNG LLP
August 11, 1999
Editorial Note on Part 1315
Editorial Note: Nomenclature changes to part appear at 82 FR 97041, Dec. 30, 2016.

§ 1315.22 Procedure for applying for individual manufacturing quotas. Any person who is registered to manufacture ephedrine, pseudoephedrine, or phenylpropanolamine and who desires to manufacture a quantity of the chemical must apply on DEA Form 189 for a manufacturing quota for the quantity of the chemical and shall state separately for each subcategory, as defined in § 1315.07, each quantity of such chemical. Copies of DEA Form 189 may be obtained from the Office of Diversion Control Web site, and must be filed (on or before April 1 of the year preceding the calendar year for which the manufacturing quota is being applied) with the UN Reporting & Quota Section, Diversion Control Division, Drug Enforcement Administration. See the Table of DEA Mailing Addresses in § 1321.01 of this chapter for the current mailing address. A separate application must be made for each chemical desired to be manufactured. The applicant must state the following: ( a ) The name and DEA Chemical Code Number, as set forth in part 1310 of this chapter, of the chemical.
( b ) For the chemical in each of the current and preceding 2 calendar years, ( 1 ) The authorized individual manufacturing quota, if any;
( 2 ) The actual or estimated quantity manufactured;
( 3 ) The actual or estimated net disposal;
( 4 ) The actual or estimated inventory allowance pursuant to § 1315.24; and
( 5 ) The actual or estimated inventory as of December 31.
( c ) For the chemical in the next calendar year, ( 1 ) The desired individual manufacturing quota; and
( 2 ) Any additional factors that the applicant finds relevant to the fixing of the individual manufacturing quota, including any of the following: ( i ) The trend of (and recent changes in) the applicant's and the national rates of net disposal.
( ii ) The applicant's production cycle and current inventory position.
( iii ) The economic and physical availability of raw materials for use in manufacturing and for inventory purposes.
( iv ) Yield and stability problems.
( v ) Potential disruptions to production (including possible labor strikes).
( vi ) Recent unforeseen emergencies such as floods and fires.
[72 FR 37448, July 10, 2007, as amended at 73 FR 73555, Dec. 3, 2008; 75 FR 10684, Mar. 9, 2010; 88 FR 60143, Aug. 31, 2023]
<PAGE>   1





                                                                    EXHIBIT 21.1



                           SUBSIDIARIES OF THE COMPANY

       SUBSIDIARY                                    STATE OF INCORPORATION
       ----------                                    -----------------------
Forcenergy International Inc.                               Delaware

Forcenergy Phenix Marin Corp.                            Virgin Islands

Forcenergy Gryphon B.V.                                    Netherlands

Forcenergy Resources Inc.                                     Texas

Forcenergy Onshore Inc.                                     Delaware

Forcenergy GOM Inc.                                         Delaware

Forcenergy Ltd.                                          Cayman Islands

Forcenergy Drilling Inc.                                    Delaware

Edisto Energy Inc.                                            Texas

Edisto Energy Canada, Inc.                                   Canada

Mint Holding Company                                          Texas
[No. 20449-5-II.

Division Two.

January 16, 1998.]

#### Weyerhaeuser Company, *Appellant,*v. Henry O. Frost, et al., *Respondent.*

Appeal from a judgment of the Superior Court for Grays Harbor County, No. 95-2-01148-5, Gordon Godfrey, J., entered March 28, 1996. *Reversed*by unpublished opinion per Armstrong, J., concurred in by Houghton, C.J., and Bridgewater, J.
§ 5.1110 FDA public information offices. ( a ) *Dockets Management Staff.* The Dockets Management Staff public room is located in rm. 1061, 5630 Fishers Lane, Rockville, MD 20852, Telephone: 301-827-6860.
( b ) *Freedom of Information Staff.* The Freedom of Information Staff's Public Reading Room is located at the address available on the agency's web site at *http://www.fda.gov .*
( c ) *Press Relations Staff.* Press offices are located in White Oak Bldg. 1, 10903 New Hampshire Ave., Silver Spring, MD 20993, Telephone: 301-827-6242; and at5001 Campus Dr., College Park, MD 20740, Telephone: 301-436-2335.
[77 FR 15962, Mar. 19, 2012, as amended at 79 FR 68114, Nov. 14, 2014; 81 FR 49895, July 29, 2016; 88 FR 45064, July 14, 2023]
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JAN-31-2000
<PERIOD-START>                             AUG-01-1999
<PERIOD-END>                               OCT-31-1999
<CASH>                                           8,239
<SECURITIES>                                         0
<RECEIVABLES>                                   80,359
<ALLOWANCES>                                   (3,857)
<INVENTORY>                                     63,728
<CURRENT-ASSETS>                               173,762
<PP&E>                                          86,489
<DEPRECIATION>                                (37,189)
<TOTAL-ASSETS>                                 266,755
<CURRENT-LIABILITIES>                          123,552
<BONDS>                                        137,525
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           192
<OTHER-SE>                                       3,748
<TOTAL-LIABILITY-AND-EQUITY>                   266,755
<SALES>                                        117,054
<TOTAL-REVENUES>                               117,054
<CGS>                                           81,063
<TOTAL-COSTS>                                   81,063
<OTHER-EXPENSES>                                20,966
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               1,911
<INCOME-PRETAX>                                 13,114
<INCOME-TAX>                                     5,033
<INCOME-CONTINUING>                              8,070
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     8,070
<EPS-BASIC>                                       0.42
<EPS-DILUTED>                                     0.41


</TABLE>
§ 500.46 Hexachlorophene in animal drugs. ( a ) The Commissioner of Food and Drugs has determined that there are no adequate data to establish that animal drugs containing hexachlorophene are safe and effective for any animal use other than in topical products for use on non-food-producing animals as part of a product preservative system at a level not to exceed 0.1 percent; that there is no information on the potential risk to humans from exposure to hexachlorophene by persons who apply animal products containing the drug at levels higher than 0.1 percent; and that there is likewise no information on human exposure to animals on which these animal drugs have been used and no information on possible residues of hexachlorophene in edible products of food-producing animals treated with new animal drugs that contain any quantity of hexachlorophene.
( b ) Animal drugs containing hexachlorophene for other than preservative use on non-food-producing animals at levels not exceeding 0.1 percent are considered new animal drugs and shall be the subject of new animal drug applications (NADA's).
( c ) Any person currently marketing animal drugs that contain hexachlorophene other than as part of a product preservative system for products used on non-food-producing animals at a level not exceeding 0.1 percent shall submit a new animal drug application, supplement an existing application, or reformulate the product by September 29, 1977. Each application or supplemental application shall include adequate data to establish that the animal drug is safe and effective. If the animal drug is currently subject to an approved new animal drug application, each reformulation shall require an approved supplemental application. The interim marketing of these animal drugs may continue until the application has been approved, until it has been determined that the application is not approvable under the provisions of § 514.111 of this chapter, or until an existing approved application has been withdrawn.
( d ) After September 29, 1977, animal drugs that contain hexachlorophene other than for preservative use on non-food-producing animals at a level not exceeding 0.1 percent that are introduced into interstate commerce shall be deemed to be adulterated within the meaning of section 501(a)(5) of the act (21 U.S.C. 351(a)(5)) unless such animal drug is the subject of a new animal drug application submitted pursuant to paragraph (c) of this section. Action to withdraw approval of new animal drug applications will be initiated if supplemental new animal drug applications have not been submitted in accordance with this section.
( e ) New animal drug applications submitted for animal drugs containing hexachlorophene for use in or on food-producing animals shall include adequate data to assure that edible products from treated animals are safe for human consumption under the labeled conditions of use.
[42 FR 33725, July 1, 1977; 42 FR 37975, July 26, 1977]
Office for Domestic Preparedness 

U.S. Department of Homeland Security 

Washington, DC 20531

ODP Information Bulletin 

No. 158 April 1, 2005 

TO All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

 All State Homeland Security Directors 

 All Urban Area Core City/Core County Points of Contact 

FROM: Matt Mayer 

 Acting Executive Director 

SUBJECT: Guidance for Developing Tactical Interoperable Communications Plans 

The Department of Homeland Security, Office of State and Local Government Coordination and 

Preparedness, Office for Domestic Preparedness (ODP), is pleased to disseminate the attached Tactical 

Interoperable Communications Planning Guidance and Template, developed in coordination with the 

SAFECOM program. The FY 2005 Homeland Security Grant Program (HSGP) guidance requires 

grantees to develop and test a plan to achieve tactical interoperable communications. The guidance also 

notes that this planning template would be released in concert with the National Preparedness Guidance, 

which is due for release under separate cover. 

Grantees have six months from the release of the guidance to develop their tactical interoperable 

communications plan and one year following its submission in which to test it through multijurisdictional exercises. (Additional information is available on pages 51-53 of the FY 2005 HSGP 

Guidance.) Each urban area receiving FY05 UASI funds must develop and test a tactical interoperable 

communications plan. If a state does not have a designated urban area, then it must identify a 

metropolitan area to develop and test the plan. This metropolitan area should be the same metropolitan 

area tasked with developing a multi-jurisdictional prevention and response plan as part of the HSPD-8 

implementation required by the FY 2005 HSGP guidance. 

ODP will host three one-day, regional training workshops on the Tactical Interoperable Communications 

Planning Guidance and Template in conjunction with the Office of Community Oriented Policing 

Services (COPS) Interoperable Communications Technology Program Workshop Series. These 

workshops will provide grantees with additional information on the planning process and will afford 

participants the opportunity to request support, if needed, through ODP’s Interoperable Communications 

Technical Assistance Program (ICTAP). The workshops are currently scheduled as follows: 

Western Region: April 13 in Denver, Colorado 

Central Region: June 3 in Columbus, Ohio 

Eastern Region: July 14 in Charlotte, North Carolina 

Invitation letters for the Western Region conference were disseminated on March 23, 2005. Copies of the 

invitation letter and attendee registration form are attached to this Information Bulletin. Invitations for 

the Central and Eastern Region conferences will be forthcoming. In the meantime, additional questions 

can be directed to either Keith Young, ICTAP Program Manager, at keith.young@dhs.gov or your State’s 

assigned Preparedness Officer.
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000813794
<NAME> N.C. RAILROAD COMPANY
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                       4,707,880
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             4,773,880
<PP&E>                                       8,152,266
<DEPRECIATION>                               (301,634)
<TOTAL-ASSETS>                              12,615,512
<CURRENT-LIABILITIES>                          663,604
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     2,141,735
<OTHER-SE>                                   9,810,173
<TOTAL-LIABILITY-AND-EQUITY>                12,615,512
<SALES>                                              0
<TOTAL-REVENUES>                                91,980
<CGS>                                                0
<TOTAL-COSTS>                                  811,365
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                719,385
<INCOME-TAX>                                    11,000
<INCOME-CONTINUING>                            730,385
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   730,385
<EPS-PRIMARY>                                     0.17
<EPS-DILUTED>                                        0
        

</TABLE>
# ORIGINAL FILED MAR 1 8 2020 Bowen Greenwood Clerk of Supreme Court State of Montana IN THE SUPREME COURT OF THE STATE OF MONTANA THE OFFICE OF THE CLERK OF SUPREME COURT

HELENA,MONTANA 59620-3003 Supreme Court No. DA 20-0126 DUANE RONALD BELANUS,

Petitioner and Appellant, v. STATE OF MONTANA and TIM FOX,

Respondents and Appellees. GRANT OF EXTENSION

Pursuant to authority granted under M.R. App.P. 26(1), Appellant is given an extension of time until May 1, 2020, to prepare, file, and serve the Appellant's brief. DATED this March 18, 2020 Bowen Greenwood Clerk ofthe Supreme Court

c: Duane Ronald Belanus, Timothy Charles Fox

PO BOX 203003 •HELENA MT •59620-3003 • TELEPHONE:(406)444-3858 •FAX:(406)444-5705 03/18/2020
Case Number: DA 20-0126
###### Editorial Note on Part 314

#### Editorial Note:

Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.

#### § 314.160 Approval of an application or abbreviated application for which approval was previously refused, suspended, or withdrawn.

Upon the Food and Drug Administration's own initiative or upon request of an applicant, FDA may, on the basis of new data, approve an application or abbreviated application which it had previously refused, suspended, or withdrawn approval. FDA will publish a notice in the Federal Register announcing the approval.

[57 FR 17995, Apr. 28, 1992]
#### § 1600.437 What method do I use to communicate to a participant the requirements for participating in a covered transaction?

To communicate to a participant the requirements described in 2 CFR 180.435, you must include provisions in the contractual documentation of the transaction to ensure compliance with 2 CFR part 180, subpart C, as supplemented by subpart C of this part. The provisions must also require the participant to include similar terms or conditions of compliance in lower-tier covered transactions.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1316 Ficin. ( a ) Ficin (CAS Reg. No. 9001-33-6) is an enzyme preparation obtained from the latex of species of the genus *Ficus,* which include a variety of tropical fig trees. It is a white to off-white powder. Its characterizing enzyme activity is that of a peptide hydrolase (EC 3.4.22.3).
( b ) The ingredient meets the general requirements and additional requirements for enzyme preparations in the Food Chemicals Codex, 3d ed. (1981), p. 110, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, 2101 Constitution Ave., NW., Washington, DC 20418, or may be examined at the Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200, and at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as GRAS as a direct food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an enzyme as defined in § 170.3(o)(9) of this chapter to hydrolyze proteins or polypeptides.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice.
[60 FR 32910, June 26, 1995, as amended at 78 FR 14666, Mar. 7, 2013]